Complementary mAb Polishing Solutions for Viral Clearance and Aggregate Removal - Register Now!
|Articles|October 15, 2002

BioPharm International

  • BioPharm International-10-01-2002
  • Volume 15
  • Issue 10

Process Validation: How Much to Do and When to Do It

by Anurag S. Rathore, Joseph F. Noferi, and Edward R. Arling from Pharmacia Corporation, and Gail Sofer, Bioreliance; Peter Watler, Amgen, Inc.; and Rhona O'Leary, Genentech, Inc. The trick to process validation, these industry experts argue, is to understand that it is a process that stretches through the whole product life cycle. Some secrets of success: Take a team approach; focus on the timing of the various stages of validation; avoid some common mistakes; and build your documentation as you go.

Related to this article

The BioPharm Brief: Room Temperature, RNA, and ADCs
CaseBioscience joins an ARPA-H effort to develop room-temperature cell therapy preservation, Novartis licenses an mRNA-encoded T-cell engager from Abogen, and AstraZeneca, Daiichi Sankyo, and Summit plan to combine Datroway with ivonescimab.